tiprankstipranks
Advertisement
Advertisement

ENTX Stock Latest News

Entera Bio Expands Share Authorization and Equity Plans
Company AnnouncementsEntera Bio Expands Share Authorization and Equity Plans
6d ago
8K
ENTX
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
PremiumTipRanks Newswire
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
7d ago
AZN
LLY
America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)
PremiumTipRanks Newswire
America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)
14d ago
ENTX
Entera Bio: Buy Rating Reiterated on De-Risked Oral PTH Platform and FDA-Supported Phase 3 Design; $9 Price Target Maintained
PremiumRatings
Entera Bio: Buy Rating Reiterated on De-Risked Oral PTH Platform and FDA-Supported Phase 3 Design; $9 Price Target Maintained
29d ago
ENTX
Entera Bio gets FDA feedback on registrational protocol for EB613
PremiumThe Fly
Entera Bio gets FDA feedback on registrational protocol for EB613
1M ago
ENTX
With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For
PremiumTipRanks NewswireWith Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For
1M ago
ENTX
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?
Premium
TipRanks Newswire
After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?
1M ago
NVO
ENTX
Entera Bio and Opko Health present preclinical data for oral peptides
Premium
The Fly
Entera Bio and Opko Health present preclinical data for oral peptides
1M ago
OPK
ENTX
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
PremiumTipRanks Newswire
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
2M ago
NVO
ARWR
Entera Bio Faces Elevated Operational Risks Amid Escalating Middle East Geopolitical Tensions
PremiumCompany Announcements
Entera Bio Faces Elevated Operational Risks Amid Escalating Middle East Geopolitical Tensions
2M ago
ENTX
Entera Bio files to sell 19.57M ordinary shares for holders
PremiumThe Fly
Entera Bio files to sell 19.57M ordinary shares for holders
3M ago
ENTX
Entera Bio Highlights Q1 2026 Progress and Financing
PremiumCompany Announcements
Entera Bio Highlights Q1 2026 Progress and Financing
3M ago
8K
ENTX
Entera Bio price target lowered to $9 from $10 at H.C. Wainwright
PremiumThe FlyEntera Bio price target lowered to $9 from $10 at H.C. Wainwright
3M ago
ENTX
Entera Bio Announces $10 Million Private Placement Financing
Premium
Company Announcements
Entera Bio Announces $10 Million Private Placement Financing
4M ago
8K
ENTX
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline
Premium
Company Announcements
Entera Bio Reports 2025 Results, Advances Oral Osteoporosis Pipeline
4M ago
8K
ENTX
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market
PremiumTipRanks Newswire
Entera May Be the 1st Winner of FDA’s New Framework Redefining the Multi Billion Dollar Osteoporosis Market
4M ago
LLY
ENTX
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy
PremiumTipRanks Newswire
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy
4M ago
CDXS
ENTX
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
PremiumTipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
5M ago
AZN
IBO
Entera Bio Submits Streamlined Phase 3 Plan for EB613
PremiumCompany Announcements
Entera Bio Submits Streamlined Phase 3 Plan for EB613
5M ago
8K
ENTX
Entera Bio submits streamlined Phase 3 protocol to U.S. FDA for EB613
PremiumThe FlyEntera Bio submits streamlined Phase 3 protocol to U.S. FDA for EB613
5M ago
ENTX
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX)
5M ago
ENTX
Entera Bio announces open market purchases of stock by board members
Premium
The Fly
Entera Bio announces open market purchases of stock by board members
5M ago
ENTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >